Jordana Joy

According to a press release, Myatro XL is the first 0.05% atropine eye drop for paediatric myopia control.

Following Phase 3 pivotal trial BRIO-II, Tenpoint Therapeutics said they hope to launch BRIMOCHOL PF in 2026

The Arise system utilises advanced algorithms to interpret corneal topography images, recommending lenses without requiring a fitting set

The novel nitric oxide-donating bimatoprost eye drop is designed to lower IOP in patients with open-angle glaucoma or ocular hypertension

One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom

The partnership with the NHS eye patient servicer will help preregistration optometrists access training in community and hospital settings

The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software

The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

Depending on results from the survey for healthcare professionals, a scope expansion for eIFUs could impact ophthalmic devices including contact lenses.

Akantior, an anti-amoebic polymer eye drop, is the first and only authorised medical product for the treatment of AK in the world, according to a news release.

The light-based therapy functions using a virtual reality headset

The UK's Royal National Institute of Blind People is the global distributor of the headset and ARxVision is partnering with the National Federation of the Blind and Vision Australia to expand global accessibility

The Retinopathy of Prematurity (ROP) Education and Support Programme is part of ROP Awareness Week, recognised from 26 February to 3 March

A strategic distribution partnership is expected to make Morrow’s eProgressive smart glasses available to consumers in the second quarter of 2024